HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy].

Abstract
The efficacy and safety of additional administration of propiverine were prospectively studied for naftopidil-resistant nocturia in patients with benign prostatic hypertrophy (BPH). Patients of 50 years and over with BPH who experienced nocturia twice a night or more and an overall International Prostate Symptom Score (IPSS) of 8 or more were first administered naftopidil (50 or 75 mg/day) for 4 weeks. Thirty subjects who did not show improvement in nocturia and requested further treatment were enrolled in the present study. Propiverine was then administered concomitantly 10 mg/day for 8 weeks. Significant improvement was observed with additional propiverine in the frequency of nocturia on voiding diary, total IPSS, voiding symptom, storage symptom and nocturnal voiding scores. No significant change was observed in the peak urinary flow rate (Qmax), mean urinary flow rate (Qave), voided urine volume, or residual urine volume. Adverse events were dysuria (2 cases), increased residual urine (6 cases), weak urine flow (1 case), thirsty (2 cases), angular cheilitis (1 case). Administration of propiverine was suspended in 7 subjects, 1 following dysuria and 6 following increased residual urine volume. The suspension of propiverine following increased residual urine volume was significantly more prevalent in subjects with pretreatment Qmax values of less than 10 ml/second or in subjects whose prostate specific antigen (PSA) levels were 2 ng/ml or more. In conclusion, the results indicate that additional administration of propiverine may be useful for the patients with BPH who have naftopidil-resistant nocturia. However, caution must be exercised regarding Qmax and PSA levels.
AuthorsNoritaka Kamimura, Shingo Hatakeyama, Shigemasa Kudo, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Kazuaki Yoshikawa, Toshiaki Kawaguchi, Shinya Takahashi, Chikara Ohyama
JournalHinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 57 Issue 2 Pg. 71-6 (Feb 2011) ISSN: 0018-1994 [Print] Japan
PMID21412038 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Adrenergic alpha-Antagonists
  • Benzilates
  • Cholinergic Antagonists
  • Naphthalenes
  • Piperazines
  • propiverine
  • naftopidil
Topics
  • Adrenergic alpha-Antagonists (administration & dosage)
  • Aged
  • Aged, 80 and over
  • Benzilates (administration & dosage)
  • Cholinergic Antagonists (administration & dosage)
  • Drug Resistance
  • Drug Therapy, Combination
  • Humans
  • Male
  • Middle Aged
  • Naphthalenes (administration & dosage)
  • Nocturia (drug therapy)
  • Piperazines (administration & dosage)
  • Prospective Studies
  • Prostatic Hyperplasia (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: